WebGemcitabine and cisplatin plus durvalumab are being evaluated in the phase 3, TOPAZ-1 study ( NCT03875235) as first-line treatment in patients with advanced biliary tract … Web28. máj 2024 · 4006 Background: There is no globally established second-line therapy after progression on GemCis in BTC. Although ABC-06 trial showed the clinical benefit of …
Cholangiocarcinoma - SlideShare
WebTopaz-1 was the first phase-III study demonstrating efficacy for the PD-L1 inhibitor durvalumab (D) in combination with gemcitabine (Gem) and cisplatin (Cis), and the combination has the potential to become a new first-line standard of care in biliary tract cancers (BTCs). Web52MO - A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC) Date 10 Sep 2024 Session Mini Oral session: GI, upper digestive Topics Tumour Site Hepatobiliary Cancers Presenters hire works yarrawonga
Download - Topaz Labs
WebRadioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial Gastroenterology JAMA Oncology JAMA Network This phase 2 clinical trial measures the 3-month response rate of selective internal radiotherapy combined with chemotherapy as well as toxic effects, … WebThis trial is registered with ClinicalTrials.gov, NCT03524508, and enrolment is complete. Findings: Between Sept 5, 2024, and Feb 18, 2024, 193 patients were screened for eligibility, of whom 174 (88 in the liposomal irinotecan plus fluorouracil and leucovorin group and 86 in the fluorouracil plus leucovorin group) were enrolled and included in ... Web10. feb 2024 · TOPAZ-1—which was funded by AstraZeneca, the manufacturer of durvalumab—enrolled 685 people with inoperable advanced biliary tract cancer. The trial … hirewriters.com login